Key facts
- It has raised $12.6M across 3 recorded rounds; the latest was Seed Round ($2.0M) in Mar 2025.
- Notable investors include Plug and Play Tech Center, Mayo Clinic Platform, Accessio Equity Group, Oktogon Ventures, STRT Holding.
- Genomate Health has filed 3 Form Ds with the SEC, most recently Mar 2025 ($2.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Genomate Health
Funding rounds
3 roundsAbout Genomate Health
Developer of a health technology platform designed to provide cancer treatment. The company's platform uses computational models that harness the knowledge of published scientific evidence and clinical experience, augmented with computational reasoning and cognitive artificial intelligence to improve, automate, and standardize personalized treatment decisions, enabling physicians to find the right targeted therapy for cancer patients based on the individual molecular profile of their tumor.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Employees
- 33
- Website
- genomate.health/
- Ownership
- Privately Held (backing)
Genomate Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Genomate Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Genomate Health in its N-PORT filings yet. We sweep new filings monthly.